Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder.

Trial Profile

Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2011

At a glance

  • Drugs Quetiapine (Primary) ; Antidepressants
  • Indications Generalised anxiety disorder; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 21 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top